Roche reports dip in first-half sales, as covid products demand declined

27 July 2023
thomas_schinecker_roche_large

Swiss pharmaceutical giant Roche (ROG: SIX) this morning revealed that sales for the first half of 2023 had dropped 2% to 29.78 billion Swiss francs ($33.01 billion), or -8% in franc terms, hit by weakness in its diagnostics division that saw booming demand during the height of the covid pandemic.

Pharmaceutical Division sales were up 8% at 22,681 million francs, while the Diagnostics Division’s revenues plunged 23% to 7,098 francs.

Group core operating profit fell 6% to 10,911 million francs, with diluted core earnings per share (EPS) declining 5% to 10.10 francs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical